Analysis Life Sciences Thank You FDA fiscal year in review: New drug approvals in the wake of the pandemic and legislative reforms
Agency IQ
OCTOBER 6, 2023
As such, it doesn’t review things like vaccines, blood products or gene therapies – those products are instead reviewed by CBER. AgencyIQ compiled these data using information in approval letters and review packages posted to the Drugs@FDA database. Data on these novel approvals is published throughout the year by both CDER and CBER.
52 
Let's personalize your content